Resche-Rigon M - Search Results

1

Permutation tests for centre effect on survival endpoints with application in an acute myeloid leukaemia multicentre study.

Biard L, Porcher R, Resche-Rigon M. Biard L, et al. Stat Med. 2014 Jul 30;33(17):3047-57. doi: 10.1002/sim.6153. Epub 2014 Mar 28. Stat Med. 2014. PMID: 24676752

2

Local influence for the subdistribution of a competing risk.

Resche-Rigon M, Chevret S. Resche-Rigon M, et al. Stat Med. 2006 Jun 15;25(11):1937-47. doi: 10.1002/sim.2354. Stat Med. 2006. PMID: 16158402

3

Analysing multicentre competing risks data with a mixed proportional hazards model for the subdistribution.

Katsahian S, Resche-Rigon M, Chevret S, Porcher R. Katsahian S, et al. Stat Med. 2006 Dec 30;25(24):4267-78. doi: 10.1002/sim.2684. Stat Med. 2006. PMID: 16960919

4

Propensity scores in intensive care and anaesthesiology literature: a systematic review.

Gayat E, Pirracchio R, Resche-Rigon M, Mebazaa A, Mary JY, Porcher R. Gayat E, et al. Intensive Care Med. 2010 Dec;36(12):1993-2003. doi: 10.1007/s00134-010-1991-5. Epub 2010 Aug 6. Intensive Care Med. 2010. PMID: 20689924

5

Dose-finding design driven by efficacy in onco-hematology phase I/II trials.

Seegers V, Chevret S, Resche-Rigon M. Seegers V, et al. Stat Med. 2011 Jun 15;30(13):1574-83. doi: 10.1002/sim.4152. Epub 2011 Mar 11. Stat Med. 2011. PMID: 21394754

6

Propensity score applied to survival data analysis through proportional hazards models: a Monte Carlo study.

Gayat E, Resche-Rigon M, Mary JY, Porcher R. Gayat E, et al. Pharm Stat. 2012 May-Jun;11(3):222-9. doi: 10.1002/pst.537. Epub 2012 Mar 12. Pharm Stat. 2012. PMID: 22411785

7

Multiple imputation for handling systematically missing confounders in meta-analysis of individual participant data.

Resche-Rigon M, White IR, Bartlett JW, Peters SA, Thompson SG; PROG-IMT Study Group. Resche-Rigon M, et al. Stat Med. 2013 Dec 10;32(28):4890-905. doi: 10.1002/sim.5894. Epub 2013 Jul 16. Stat Med. 2013. PMID: 23857554

8

Assessing assay agreement estimation for multiple left-censored data: a multiple imputation approach.

Lapidus N, Chevret S, Resche-Rigon M. Lapidus N, et al. Stat Med. 2014 Dec 30;33(30):5298-309. doi: 10.1002/sim.6319. Epub 2014 Oct 8. Stat Med. 2014. PMID: 25292387

9

Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: negative impact of baseline corticosteroids.

Chasset F, Pages C, Biard L, Roux J, Sidina I, Madelaine I, Basset-Seguin N, Viguier M, Madjlessi-EzrA N, Schneider P, Bagot M, Resche-Rigon M, Lebbe C. Chasset F, et al. Eur J Dermatol. 2015 Jan-Feb;25(1):36-44. doi: 10.1684/ejd.2014.2471. Eur J Dermatol. 2015. PMID: 25500362

10

Long-term outcome of infliximab in severe chronic and refractory systemic sarcoidosis: a report of 16 cases.

Chapelon-Abric C, Saadoun D, Biard L, Sene D, Resche-Rigon M, Hervier B, Costedoat-Chalumeau N, Drier A, Leger JM, Cacoub P. Chapelon-Abric C, et al. Clin Exp Rheumatol. 2015 Jul-Aug;33(4):509-15. Epub 2015 Jun 29. Clin Exp Rheumatol. 2015. PMID: 26120779

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

260 results

Search Page

Filters